Gilead Sciences, Inc. $GILD Shares Sold by Integrated Advisors Network LLC

Integrated Advisors Network LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 72.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,160 shares of the biopharmaceutical company’s stock after selling 5,666 shares during the quarter. Integrated Advisors Network LLC’s holdings in Gilead Sciences were worth $301,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences during the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its holdings in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $26,000. Wealth Preservation Advisors LLC increased its stake in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC purchased a new position in Gilead Sciences in the fourth quarter valued at approximately $28,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of GILD traded down $5.01 during mid-day trading on Friday, reaching $129.83. 5,934,235 shares of the company’s stock were exchanged, compared to its average volume of 7,886,756. The business’s fifty day simple moving average is $129.78 and its 200-day simple moving average is $134.96. The stock has a market capitalization of $161.19 billion, a PE ratio of 17.69 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $107.75 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the firm earned $1.81 EPS. Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares in the company, valued at $15,395,077.28. This trade represents a 2.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. This represents a 1.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,000 shares of company stock valued at $10,824,500 over the last three months. 0.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

GILD has been the subject of several recent analyst reports. Citigroup boosted their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research report on Monday, July 6th. Morgan Stanley decreased their price objective on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating for the company in a research note on Wednesday. The Goldman Sachs Group raised their price objective on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Finally, Rothschild & Co Redburn cut their target price on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Twenty-six equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $159.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.